Highly Multiplexed with Comprehensive Coverage
Built on the same innovative technology that forms the foundation of the NanoString Gene Expression CodeSets, the nCounter® miRNA Expression Assays are capable of highly multiplexed, direct digital detection and counting of miRNAs in a single reaction without amplification.
Publishing with the nCounter miRNA Expression Assays
nCounter miRNA Expression Assays have been used to profile miRNAs from a variety of sample types, in a wide range of biological areas of research, including cell signaling and cancer biology, neuroscience, stem cell research, autophagy, infectious disease, and immunology.
NanoString’s FFPE-compatible chemistry allows for tens of thousands of data points to be generated per day in clinically relevant sample types important in translational research.
Christmann R. et al. (2016) performed biomarker analysis on tissue samples from patients with SSc-ILD to find miR-155 in the progression of lung fibrosis in systemic sclerosis using the nCounter Human v3 miRNA Expression Assay.
Luciano C. et al. (2013) found interesting integrated miRNA and mRNA signatures associated with survival in triple-negative breast cancer using the miRGE™ Assays (simultaneous analysis of miRNA and mRNA on the same sample).
The discovery of relatively stable, extracellular miRNAs in serum and plasma has generated huge interest as non-invasive biomarkers for a variety of diseases.
Permuth-Wey J. et al. (2015) discovered novel miRNA biomarkers in plasma samples for patients with intraductal papillary mucinous neoplasms of the pancreas using the nCounter Human v3 miRNA Expression Assay.
Stylli S.S. et al. (2016) profiled miRNA in cerebrospinal fluid in patients with aneurysmal subarachnoidhemorrhage using the nCounter Human v3 miRNA Expression Assay.
NanoString profiling indicates differential serum expression levels of circulating miRNAs in healthy controls and children with mild or severe symptoms of EV71. Read more in Elevated expression of circulating miR876-5p is a specific response to severe EV71 infections by Wang R. et al. (2016).
Exosomal miRNAs play an important role in disease progression and can stimulate angiogenesis and facilitate metastasis in cancers.
Topol A. et al. (2016) used the nCounter Human v3 miRNA Expression Assay to study dysregulation of miRNA-9 in a subset of schizophrenia patent-derived neural progenitor cells.
Rodosthenis S. et al. (2016) performed a pilot study of older individuals by studying ambient particulate matter and miRNA in extracellular vesicles.
miRNAs have been identified as potential cancer biomarkers due to their presence and stability in many body fluids including urine.
Armstrong D.A. et al. (2015) profiled miRNA from matched tumor and biofluids in bladder cancer using the nCounter Human v3 miRNA Expression Assay.
See the complete list of publications using nCounter miRNA Expression Assays here
For more information, click here.